Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 10/20 | 0.37 |
| ▸ | ACACB | O00763 | 5/20 | 0.33 |
| ▸ | ACACA | Q13085 | 5/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097153 | 0.94 | CASR (0.34) | CASRACACBACACACCR5ALOX5 | |
| SCHEMBL1096063 | 0.86 | CASR (0.39) | CASRCCR5 | |
| SCHEMBL1095449 | 0.86 | TTR (0.40) | CASRCCR5 | |
| SCHEMBL1095501 | 0.86 | CASR (0.43) | CASR | |
| SCHEMBL1096415 | 0.86 | P2RY12 (0.37) | CASR | |
| SCHEMBL1095567 | 0.83 | CASR (0.36) | CASRACACBCCR5 | |
| SCHEMBL1096960 | 0.82 | CASR (0.41) | CASRCCR5 | |
| SCHEMBL1095781 | 0.82 | CCR5 (0.39) | CASRCCR5 | |
| SCHEMBL1095686 | 0.82 | CCR5 (0.34) | CASRCCR5 | |
| SCHEMBL1097108 | 0.81 | PTGER1 (0.38) | CASRCCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2085383-A1 | PIPERIDINE DERIVATIVES OR SALTS THEREOF | Astellas Pharma Inc. (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | CASR 1/4885ACACB 4469/4885ACACA 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.